First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

NCT01337154 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

140

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis showed that the primary endpoint would not be met.

Conditions

Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: Tamibarotene
DRUG: Placebo

Sponsor

CytRx